[go: up one dir, main page]

EP1711168A2 - Orale pharmazeutische zusammensetzungen von candesartan cilexetil - Google Patents

Orale pharmazeutische zusammensetzungen von candesartan cilexetil

Info

Publication number
EP1711168A2
EP1711168A2 EP05702309A EP05702309A EP1711168A2 EP 1711168 A2 EP1711168 A2 EP 1711168A2 EP 05702309 A EP05702309 A EP 05702309A EP 05702309 A EP05702309 A EP 05702309A EP 1711168 A2 EP1711168 A2 EP 1711168A2
Authority
EP
European Patent Office
Prior art keywords
pharmaceutical composition
acid
composition according
candesartan cilexetil
fatty
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05702309A
Other languages
English (en)
French (fr)
Inventor
Romi Barat Singh
Girish K. S/o K.S. Karanth KARANTH
Vishnubhotla Naga Prasad
Sanjeev Kumar Sethi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of EP1711168A2 publication Critical patent/EP1711168A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • the present invention relates to pharmaceutical compositions of candesartan cilexetil and processes for their preparation.
  • Candesartan is a selective ATi subtype angiotensin II receptor antagonist.
  • angiotensin II receptor antagonists have attracted attention as effective agents for the treatment of hypertension in conjunction with angiotensin I converting enzyme (ACE) inhibitors.
  • ACE angiotensin I converting enzyme
  • Candesartan cilexetil is a prodrug that is hydrolyzed in the gastrointestinal tract during absorption to form candesartan. It falls in the class of benzimidazole -7- carboxylic acids and their derivatives. These agents exhibit a stronger and more effective hypotensive action when compared to other classes of ACE inhibitors. They also are less likely to cause coughing as a side effect.
  • Candesartan cilexetil is stable against temperature, moisture and light when it is alone in the solid state. However, when it is prepared into tablets and incorporated in with other ingredients, it has been observed that the active ingredient degrades over time.
  • U.S. Patent No. 5,534,534 discloses that the reduction in the content of the candesartan cilexetil with the lapse of time in pharmaceutical compositions can be reduced by incorporating oily substances having a low melting point in these compositions.
  • the oily substance is incorporated with the active component to form a stable composition that suppresses the decomposition over time that is caused by compression.
  • the resulting composition is described as being stable with minimal crystalline disorder.
  • the stability of pharmaceutical compositions of candesartan cilexetil can also be correlated to various degradation products, such as desethyl candesartan and other related substances. The levels of these related substances serve as a measure of the composition's overall stability.
  • a pharmaceutical composition that includes a candesartan cilexetil and one or more fatty substances being present at a concentration of about 0.5% to about 10% w/w.
  • the fatty substances may be lipids and phospholipids.
  • the lipids may be fatty acids and fatty acid esters.
  • the fatty acids may be one or more of lauric acid, myristic acid, stearic acid, palmitoleic acid, oleic acid, capric acid, caprylic acid, oleic acid, linoleic acid, arachidonic acid and mixtures thereof.
  • the fatty acid esters may be one or more of glycerol stearate, glycerol palmitate, glyceryl caprate, glyceryl caprylate, glyceryl caprylate/ caprate, glycerol oleate, glycerol linoleate, glyceryl lauropalmitooleate and mixtures thereof.
  • the phospholipids may be phosphoglycerides and sphingolipids.
  • the phosphoglycerides maybe one or more of lecithin, cephalin, soyalecithin, egglecithin, phosphatidylserine, phosphatidyl-inositol and mixtures thereof.
  • the candesartan cilexetil may be present in the pharmaceutical composition in a range of about 2% to about 35% w/w.
  • the composition may further include one or more pharmaceutically acceptable excipients.
  • the one or more pharmaceutically acceptable excipients maybe one or more of fillers, binders, disintegrants, lubricants, coloring and • flavoring agents.
  • the pharmaceutical composition may be in the form of a tablet or a capsule and the tablet may further include a coating, the coating including one or more functional and/or non-functional layers.
  • a process for the preparation of a pharmaceutical composition includes dispersing candesartan cilexetil and one or more fatty substances at a concentration of about 0.5% to about 10%w/w in a binder solution to form a dispersion; granulating the dispersion with one or more fillers and the one or more disintegrants to form granules; and drying, sizing, lubricating and compressing the granules into tablets.
  • Embodiments of the process may include one or more of the following features or those described above.
  • the dispersion may f rther include one or more fillers.
  • the dispersion also may further include one or more disintegrants.
  • the granulation may be wet granulation and/or dry granulation.
  • a method for the treatment of hypertension in a patient in need thereof includes administering a pharmaceutical composition that includes candesartan cilexetil and one or more fatty substances at a concentration of about 0.5% to about 10% w/w.
  • Embodiments of the method treatment may include one or more of the following features or those described above.
  • the fatty substances may include lipids and phospholipids.
  • the candesartan cilexetil may be present in a range of about 2% to about 35% w/w.
  • the present inventors have now surprising found that the use of fatty substances at a concentration of about 0.5% to about 10% w/w of the total composition results in stable pharmaceutical compositions of candesartan cilexetil. These pharmaceutical formulations have low levels of impurities, in particular desethyl candesartan and other related substances. Further, the present invention provides an economical method of stabilizing pharmaceutical compositions of candesartan cilexetil and enhances the shelf life of the product.
  • candesartan cilexetil refers to a prodrug that is hydrolyzed to form candesartan during its absorption from the gastrointestinal tract.
  • Candesartan cilexetil may be present at a concentration range of about 2% to about 35% w/w, and particularly from about 3% to about 30% w/w, based on the total weight of the composition.
  • the pharmaceutical composition of candesartan may also include one or more other active agents. Suitable other active agents include one or more diuretics, sympathoplegic agents, vasodilators, ACE inhibitors and angiotensin receptor antagonists. In each case, the other active agent may be in the free form or in the form of a pharmaceutically acceptable salt.
  • the term 'stabilized pharmaceutical composition' refers to a composition capable of maintaining excellent stability with respect to the levels of impurities, especially desethyl candesartan and other total related substances.
  • Suitable stabilizing agents include one or more fatty substances.
  • Suitable fatty substances include one or more of lipids, phospholipids and mixtures thereof.
  • Lipids include fatty acids and fatty acid esters.
  • the one or more fatty substance may be present in a concentration of about 0.5% to about 10% w/w, particularly from about 1% to about 5% w/w, based on the total weight of the composition.
  • Suitable fatty acids include one or more of lauric acid, myristic acid, stearic acid, palmitoleic acid, oleic acid, capric acid, caprylic acid, oleic acid, linoleic acid, arachidonic acid and mixtures thereof.
  • Suitable fatty acid esters include one or more of glycerol stearate, glycerol palmitate, glyceryl caprate, glyceryl caprylate, glyceryl caprylate/caprate, glycerol oleate, glycerol linoleate, glyceryl lauropalmitooleate and mixtures thereof.
  • Suitable phospholipids include phosphoglycerides, sphingolipids and mixtures thereof.
  • Suitabe phosphoglycerides include one or more of lecithin, cephalin, soyalecithin, egglecithin , phosphatidylserine, phosphatidyl-inositol and mixtures thereof.
  • compositions described herein may also include one or more pharmaceutically acceptable excipients.
  • the pharmaceutical compositions may be prepared by processes known in the prior art, such as wet granulation, dry granulation and direct compression.
  • the pharmaceutical compositions may be in the form of tablets or capsules.
  • processes for the preparation of pharmaceutical compositions of candesartan cilexetil The process includes dispersing candesartan cilexetil and one or more fatty substances in the binder solution to form a dispersion.
  • the dispersion is then granulated with one or more fillers and one or more disintegrants to form granules.
  • the granules are then dried, sized, lubricated and compressed into tablets.
  • compositions of candesartan cilexetil may also be prepared by dispersing candesartan cilexetil, one or more fatty substances and one or more fillers in binder solution to form a dispersion.
  • the dispersion is then granulated with one or more fillers and one or more disintegrants.
  • the granules are then dried, sized, lubricated and compressed into tablets.
  • compositions of candesartan cilexetil may also may be prepared by dispersing candesartan cilexetil, one or more fatty substances and one or more distintegrants in a binder solution to form a dispersion. The dispersion then is granulated with one or more disintegrants and one or more fillers. The granules then are dried, sized, lubricated, and compressed into tablets.
  • Suitable pharmaceutically acceptable excipients include one or more of fillers, binders, disintegrants, lubricants, glidants, colors and mixtures thereof.
  • Suitable fillers include one or more of corn starch, lactose, white sugar, sucrose, sugar compressible, sugar confectioners, glucose, sorbitol, calcium carbonate, calcium phosphate-dibasic, calcium phosphate-tribasic, calcium sulfate, microcrystalline cellulose, silicified microcrystalline cellulose, cellulose powdered, dextrates, dextrins, dextrose, fructose, kaolin, lactitol, mannitol, sorbitol, starch, starch pregelatinized and mixtures thereof.
  • Suitable binders include one or more of methyl cellulose, hydroxypropyl cellulose, polyvinylpyrrolidone, gelatin, gum Arabic, ethyl cellulose, polyvinyl alcohol, pullulan, pregelatinized starch, agar, tragacanth, sodium alginate, propylene glycol and mixtures thereof.
  • Suitable disintegrants include one or more of calcium carboxymethyl cellulose, colloidal silicon dioxide, starch, croscarmellose sodium, crospovidone, sodium starch glycolate and mixtures thereof.
  • Suitable lubricants and glidants include one or more of colloidal anhydrous silica, stearic acid, magnesium stearate, calcium stearate, talc, hydrogenated castor oil, sucrose esters of fatty acids, microcrystalline wax, yellow beeswax, white beeswax and mixtures thereof.
  • Suitable coloring agents include any FDA approved colors for oral use.
  • the tablets may also be coated with one or more additional layers of film forming agents and/or pharmaceutically acceptable excipients.
  • the coating layers over the tablet may be applied as a solution/dispersion of the coating ingredients using any conventional technique known in the prior art. Such processes include spray coating in a conventional coating pan or fluidized bed processor and dip coating. Suitable solvents used for preparing a solution/dispersion of the coating ingredients include one or more of methylene chloride, isopropyl alcohol, acetone, methanol, ethanol, water and mixtures thereof.
  • Suitable film forming agents include one or more of ethyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl cellulose, methyl cellulose, carboxymethylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropyl methyl phthalate, cellulose acetate, cellulose acetate trimelliatate, cellulose acetate phthalate; waxes, such as polyethylene glycol; methacrylic acid polymers, such as Eudragit ® RL and RS; and mixture thereof.
  • commercially available coating compositions comprising film-forming polymers marketed under various trade names, such as Opadry® may also be used for coating.
  • the following examples are illustrative of the invention, and are not to be construed as limiting the invention. EXAMPLE 1
  • Candesartan cilexetil and glyceryl caprate were dispersed in a solution of hydroxypropyl cellulose in water.
  • Candesartan cilexetil, glyceryl caprylate and a part of the lactose were dispersed in a solution of hydroxypropyl cellulose in water.
  • the wet granules were dried in a fluid bed drier, passed through a screen and then sized.
  • Candesartan cilexetil, soyalecithin and a part of the calcium carboxymethyl cellulose were dispersed in a solution of hydroxypropyl cellulose in water.
  • the magnesium stearate was then passed through a screen, blended with the blend of step 4 and the total mixture compressed into tablets.
  • the one or more fatty substances show a stabilizing effect on candesartan cilexetil.
  • Table 1 compares stability data at various intervals (40°C/75%RH) with reference to the amount of desethyl candesartan and total related substances found. TABLE 1
  • Table 1 indicates that the use of one or more fatty substances stabilizes the candesartan cilexetil compositions.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP05702309A 2004-01-23 2005-01-21 Orale pharmazeutische zusammensetzungen von candesartan cilexetil Withdrawn EP1711168A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN127DE2004 2004-01-23
PCT/IB2005/000148 WO2005079751A2 (en) 2004-01-23 2005-01-21 Oral pharmaceutical compositions of candesartan cilexetil

Publications (1)

Publication Number Publication Date
EP1711168A2 true EP1711168A2 (de) 2006-10-18

Family

ID=34878773

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05702309A Withdrawn EP1711168A2 (de) 2004-01-23 2005-01-21 Orale pharmazeutische zusammensetzungen von candesartan cilexetil

Country Status (2)

Country Link
EP (1) EP1711168A2 (de)
WO (1) WO2005079751A2 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2165702A1 (de) 2008-09-17 2010-03-24 Helm AG Durch Nassgranulation hergestellte stabile und fertig gelöste Zusammensetzungen aus Candesartan-Cilexetil

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI494134B (zh) * 2006-06-20 2015-08-01 Siegfried Generics Int Ag 含有坎地沙坦酯的組成物、錠劑和顆粒及該錠劑的製造方法
AU2007293727A1 (en) * 2006-09-05 2008-03-13 Astrazeneca Ab Pharmaceutical composition comprising candesartan cilexetil
WO2008045006A1 (en) * 2006-10-11 2008-04-17 Fako Ilaclari A. S. Formulations of candesartan
EP2099431B1 (de) * 2006-11-28 2013-06-05 Laboratorios Liconsa, S.A. Stabilisierte feste pharmazeutische zusammensetzung von candesartan cilexetil
WO2008084504A2 (en) * 2007-01-12 2008-07-17 Rubicon Research Private Limited Pharmaceutical compositions of angiotensin ii receptor blockers
EP1952806A1 (de) 2007-02-01 2008-08-06 Helm AG Herstellungsverfahren für Candesartan-Adsorbate
PL384680A1 (pl) * 2007-03-28 2008-09-29 Zak & Lstrok Ady Farmaceutyczn Kompozycja farmaceutyczna zawierająca kandesartan cyleksetylu oraz sposób jej wytwarzania
KR20100046216A (ko) * 2007-08-01 2010-05-06 테바 파마슈티컬 인더스트리즈 리미티드 칸데사르탄의 약학 조성물
DE102007052070A1 (de) 2007-10-30 2009-05-07 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Candesartancilexetil
DE102008059206A1 (de) 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
ES2364011B1 (es) 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
JP5860480B2 (ja) 2011-01-11 2016-02-16 キャプシュゲル・ベルジウム・エヌ・ヴィ プルランを含む新しい硬カプセル
IN2014DN09045A (de) 2012-05-07 2015-05-22 Bayer Pharma AG
CN103127012B (zh) * 2013-02-17 2015-04-22 杭州澳医保灵药业有限公司 一种依巴斯汀分散片及其制备方法
EP3609476B1 (de) 2017-04-14 2025-06-04 Capsugel Belgium NV Pullulankapseln
AU2018253392B2 (en) 2017-04-14 2023-11-02 Capsugel Belgium Nv Process for making pullulan
CN117442577B (zh) * 2023-12-21 2024-03-15 山东则正医药技术有限公司 一种坎地沙坦酯微片及制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW284688B (de) * 1991-11-20 1996-09-01 Takeda Pharm Industry Co Ltd
DE19820151A1 (de) * 1998-05-06 1999-11-11 Hexal Ag Transdermales therapeutisches System zur Anwendung von Candesartan
CA2363792C (en) * 1999-02-19 2009-10-27 Takeda Chemical Industries, Ltd. Percutaneous absorption preparation of compound having angiotensin ii antagonistic activity
WO2002015935A1 (en) * 2000-08-25 2002-02-28 Takeda Chemical Industries, Ltd. Fibrinogen lowering agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2005079751A2 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2165702A1 (de) 2008-09-17 2010-03-24 Helm AG Durch Nassgranulation hergestellte stabile und fertig gelöste Zusammensetzungen aus Candesartan-Cilexetil

Also Published As

Publication number Publication date
WO2005079751A2 (en) 2005-09-01
WO2005079751A3 (en) 2006-03-30

Similar Documents

Publication Publication Date Title
EP1711168A2 (de) Orale pharmazeutische zusammensetzungen von candesartan cilexetil
JP2021178871A (ja) エンザルタミドの製剤
TWI564008B (zh) 難溶性藥物之溶解性改善製劑
US20110136883A1 (en) Granulation of active pharmaceutical ingredients
JPWO2009066773A1 (ja) 口腔内崩壊錠
KR20130091319A (ko) 4-아미노-5-플루오로-3-[6-(4-메틸피페라진-1-일)-1ｈ-벤즈이미다졸-2-일]-1ｈ-퀴놀린-2-온 락테이트 일수화물을 포함한 제약 조성물
CA2801020A1 (en) A stable pharmaceutical formulation comprising telmisartan and hydrochlorothiazide
EP3606511A1 (de) Pharmazeutische zusammensetzungen mit lenvatinib-mesylat
CA2644179C (en) Novel pharmaceutical composition comprising a disintegration matrix
WO2014090386A1 (en) Orally disintegrating tablet containing asenapine
WO2005084648A1 (en) Pharmaceutical compositions comprising candesartan cilexetil
WO2005070398A2 (en) Pharmaceutical compositions of candesartan cilexetil stabilized with co-solvents
US20040037880A1 (en) Extended release formulation of divalproex sodium
JP7322475B2 (ja) アジルサルタンを含有する錠剤
WO2019180735A1 (en) Stable pharmaceutical compositions comprising sacubitril-valsartan complex
WO2012147101A2 (en) Pharmaceutical compositions of raltegravir, methods of preparation and use thereof
KR20100083047A (ko) 생체이용률이 향상된 발사르탄을 포함하는 약제학적 조성물
EP2139456A1 (de) Pharmazeutische zusammensetzung mit candesartan-cilexetil und herstellungsverfahren dafür
JP7322474B2 (ja) アジルサルタンを含有する錠剤
MX2015004973A (es) Formulaciones de compuestos derivados de pirimidindiona.
JP3597823B2 (ja) 固形製剤
EP2153822A1 (de) Granulation von aktiven pharmazeutischen Inhaltsstoffen
JP2016510787A (ja) クリゾチニブを含む剤形
WO2006013444A1 (en) Preparations of stable pharmaceutical compositions of nateglinide and processes for their preparation
WO2005016315A1 (en) Pharmaceutical compositions of nateglinide and a high amount of a water-soluble filler

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR LV MK YU

17P Request for examination filed

Effective date: 20061002

RBV Designated contracting states (corrected)

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20070522

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070801